Topical tacrolimus as treatment of atopic dermatitis

Masutaka Furue, Satoshi Takeuchi

研究成果: ジャーナルへの寄稿評論記事

1 引用 (Scopus)

抄録

Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Topical tacrolimus has been widely recognized in terms of its short- and long-term efficacies and safety, and it is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. To reduce possible long-term adverse effects, it is important to monitor its topical doses in daily clinics.

元の言語英語
ページ(範囲)161-166
ページ数6
ジャーナルClinical, Cosmetic and Investigational Dermatology
2
出版物ステータス出版済み - 12 1 2009

Fingerprint

Tacrolimus
Atopic Dermatitis
Eczematous Skin Diseases
Steroids
Therapeutics
Disease Progression
Inflammation
Safety
Calcineurin Inhibitors

All Science Journal Classification (ASJC) codes

  • Dermatology

これを引用

Topical tacrolimus as treatment of atopic dermatitis. / Furue, Masutaka; Takeuchi, Satoshi.

:: Clinical, Cosmetic and Investigational Dermatology, 巻 2, 01.12.2009, p. 161-166.

研究成果: ジャーナルへの寄稿評論記事

@article{a6b21f551221491d82011a685bdefe04,
title = "Topical tacrolimus as treatment of atopic dermatitis",
abstract = "Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Topical tacrolimus has been widely recognized in terms of its short- and long-term efficacies and safety, and it is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. To reduce possible long-term adverse effects, it is important to monitor its topical doses in daily clinics.",
author = "Masutaka Furue and Satoshi Takeuchi",
year = "2009",
month = "12",
day = "1",
language = "English",
volume = "2",
pages = "161--166",
journal = "Clinical, Cosmetic and Investigational Dermatology",
issn = "1178-7015",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Topical tacrolimus as treatment of atopic dermatitis

AU - Furue, Masutaka

AU - Takeuchi, Satoshi

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Topical tacrolimus has been widely recognized in terms of its short- and long-term efficacies and safety, and it is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. To reduce possible long-term adverse effects, it is important to monitor its topical doses in daily clinics.

AB - Atopic dermatitis (AD) is a common, chronic, relapsing, severely pruritic, eczematous skin disease. The mainstays of treatment for AD are topical tacrolimus and topical steroids. Tacrolimus, a calcineurin inhibitor, not only complements existing treatment options but also overcomes some of the drawbacks of topical steroid therapy when given topically and thus meets the long-term needs of patients in preventing disease progression. Topical tacrolimus has been widely recognized in terms of its short- and long-term efficacies and safety, and it is also accepted as a first-line treatment for inflammation in AD. The recent proactive use of topical tacrolimus may emphasize a long-term benefit of this calcineurin inhibitor for AD treatment. To reduce possible long-term adverse effects, it is important to monitor its topical doses in daily clinics.

UR - http://www.scopus.com/inward/record.url?scp=77953404924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953404924&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77953404924

VL - 2

SP - 161

EP - 166

JO - Clinical, Cosmetic and Investigational Dermatology

JF - Clinical, Cosmetic and Investigational Dermatology

SN - 1178-7015

ER -